About: ⁹⁰Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study   Goto Sponge  NotDistinct  Permalink

An Entity of Type : owl:Thing, within Data Space : data.idref.fr associated with source document(s)

AttributesValues
Author
Bibliographic Citation
  • Chevallier Patrice, Eugène Thomas, Robillard Nelly, Isnard Françoise, Nicolini Franck, Escoffre Barbe Martine, Huguet Françoise, Hunault Mathilde, Marçais Antoine, Gaschet Joëlle, Cherel Michel, Guillaume Thierry, Delaunay Jacques, Peterlin Pierre, Eveillard Marion, Thomas Xavier, Ifrah Norbert, Lapusan Simona, Bodet-Milin Caroline, Barbet Jacques, Faivre-Chauvet Alain, Ferrer Ludovic, Bene Marie, Le Houerou Claire, Goldenberg David, Wegener William, Kraeber-Bodéré Françoise. ⁹⁰Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet, Elsevier, 2015, 2 (3), pp.e108-17. ⟨10.1016/S2352-3026(15)00020-4⟩
  • Chevallier Patrice, Eugène Thomas, Robillard Nelly, Isnard Françoise, Nicolini Franck, Escoffre Barbe Martine, Huguet Françoise, Hunault Mathilde, Marçais Antoine, Gaschet Joëlle, Cherel Michel, Guillaume Thierry, Delaunay Jacques, Peterlin Pierre, Eveillard Marion, Thomas Xavier, Ifrah Norbert, Lapusan Simona, Bodet-Milin Caroline, Barbet Jacques, Faivre-Chauvet Alain, Ferrer Ludovic, Bene Marie, Le Houerou Claire, Goldenberg David, Wegener William, Kraeber-Bodéré Françoise. ⁹⁰Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. The Lancet, Elsevier, 2015, 2 (3), pp.e108-17. ⟨10.1016/S2352-3026(15)00020-4⟩
  • Chevallier Patrice, Eugène Thomas, Robillard Nelly, Isnard Françoise, Nicolini Franck, Escoffre Barbe Martine, Huguet Françoise, Hunault Mathilde, Marçais Antoine, Gaschet Joëlle, Cherel Michel, Guillaume Thierry, Delaunay Jacques, Peterlin Pierre, Eveillard Marion, Thomas Xavier, Ifrah Norbert, Lapusan Simona, Bodet-Milin Caroline, Barbet Jacques, Faivre-Chauvet Alain, Ferrer Ludovic, Bene Marie, Le Houerou Claire, Goldenberg David, Wegener William, Kraeber-Bodéré Françoise . ⁹⁰Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study . The Lancet, 2015, 2 (3), pp.e108-17 . ⟨10.1016/S2352-3026(15)00020-4⟩
  • Chevallier Patrice, Eugène Thomas, Robillard Nelly, Isnard Françoise, Nicolini Franck, Escoffre Barbe Martine, Huguet Françoise, Hunault Mathilde, Marçais Antoine, Gaschet Joëlle, Cherel Michel, Guillaume Thierry, Delaunay Jacques, Peterlin Pierre, Eveillard Marion, Thomas Xavier, Ifrah Norbert, Lapusan Simona, Bodet-Milin Caroline, Barbet Jacques, Faivre-Chauvet Alain, Ferrer Ludovic, Bene Marie, Le Houerou Claire, Goldenberg David, Wegener William, Kraeber-Bodéré Françoise. ⁹⁰Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. The Lancet, 2015, 2 (3), pp.e108-17. ⟨10.1016/S2352-3026(15)00020-4⟩
Title
  • ⁹⁰Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study
dc:date
  • 2015
Digital Object Identifier (DOI)
  • 10.1016/S2352-3026(15)00020-4
Faceted Search & Find service v1.13.91 as of Aug 16 2018


Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software